Jeffrey J. Sutherland, Ph.D.
Affiliations: | 2004 | Queen's University, Canada, Kingston, Ontario, Canada |
Area:
Pharmaceutical ChemistryGoogle:
"Jeffrey Sutherland"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Donald F. Weaver | grad student | 2001-2004 | Queen's University, Canada | |
| (The development and application of quantitative structure-activity relationship and classification techniques for virtual screening in drug design.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Copple IM, den Hollander W, Callegaro G, et al. (2018) Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury. Archives of Toxicology |
| Lee JA, Shinn P, Jaken S, et al. (2015) Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays. Plos One. 10: e0130796 |
| Sutherland JJ, Gao C, Cahya S, et al. (2013) What general conclusions can we draw from kinase profiling data sets? Biochimica Et Biophysica Acta. 1834: 1425-33 |
| Sutherland JJ, Raymond JW, Stevens JL, et al. (2012) Relating molecular properties and in vitro assay results to in vivo drug disposition and toxicity outcomes. Journal of Medicinal Chemistry. 55: 6455-66 |
| Nandigam RK, Evans DA, Erickson JA, et al. (2008) Predicting the accuracy of ligand overlay methods with Random Forest models. Journal of Chemical Information and Modeling. 48: 2386-94 |
| Sutherland JJ, Higgs RE, Watson I, et al. (2008) Chemical fragments as foundations for understanding target space and activity prediction. Journal of Medicinal Chemistry. 51: 2689-700 |
| Sutherland JJ, Nandigam RK, Erickson JA, et al. (2007) Lessons in molecular recognition. 2. Assessing and improving cross-docking accuracy. Journal of Chemical Information and Modeling. 47: 2293-302 |
| O'Brien LA, Sutherland JJ, Weaver DF, et al. (2005) Theoretical structural explanation for Group I and Group II, type 2A von Willebrand disease mutations. Journal of Thrombosis and Haemostasis : Jth. 3: 796-7 |
| Sutherland JJ, Weaver DF. (2004) Three-dimensional quantitative structure-activity and structure-selectivity relationships of dihydrofolate reductase inhibitors. Journal of Computer-Aided Molecular Design. 18: 309-31 |
| Sutherland JJ, O'Brien LA, Weaver DF. (2004) A comparison of methods for modeling quantitative structure-activity relationships. Journal of Medicinal Chemistry. 47: 5541-54 |